嵌合抗原受体T细胞治疗恶性淋巴瘤研究进展

Progress of chimeric antigen receptor T-cell for treatment of malignant lymphoma

嵌合抗原受体T细胞（CAR-T）是治疗复发难治性恶性淋巴瘤的有效手段之一，如何提高疗效、控制不良反应是当前研究的重点。几项CD19CAR—T治疗B细胞淋巴瘤的大型临床研究证实疗效得到改善，不良反应可控制。CD19CAR-T治疗后肿瘤细胞抗原丢失的问题是其治疗失败的主要原因，以新型靶点如CD22治疗B细胞淋巴瘤、CD30治疗霍奇金淋巴瘤等CAR-T的临床研究，进一步提高了CAR—T的有效性。环磷酰胺或苯达莫司汀加氟达拉滨的联合预处理方案可改善CAR—T治疗的有效率。

Chimeric antigen receptor T-cell （CAR-T） is one of the effective methods for treatment of lymphoma. The way to improve the efficacy and control the reverse reactions still needs to be explored further. Several clinical trials have indicated CAR-T could have favorable effects on the B-cell lymphoma patients with controllable reverse reactions. However, antigen loss is a major factor for the acquired resistance to CD19 CAR-T therapy. Other clinical researches, including CD22 for treatment of B-cell lymphoma and CD30 for Hodgkin lymphoma, have increased the efficacy of CAR-T. Moreover, lots of trials have suggested that the patients who received cyclopbosphamide or bendamustine plus fludarabine lymphodepletion can get a high effective rate.